Smart nanocarriers in triple-negative breast cancer: recent advances in targeting and translational application.

IF 6.9 3区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Drug Delivery and Translational Research Pub Date : 2026-08-01 Epub Date: 2025-12-04 DOI:10.1007/s13346-025-02022-4
Aparana Mishra, Vitthal L Gole, Smriti Ojha
{"title":"Smart nanocarriers in triple-negative breast cancer: recent advances in targeting and translational application.","authors":"Aparana Mishra, Vitthal L Gole, Smriti Ojha","doi":"10.1007/s13346-025-02022-4","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer remains one of the most prevalent causes of cancer-related mortality worldwide. Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer that has a poor prognosis and limited therapeutic options. Smart nanocarriers have been developed through significant advancements in nanotechnology over the past few years. To increase therapeutic effectiveness while reducing systemic toxicity, recent developments in nanotechnology have led to the creation of smart nanocarriers-nanosystems designed to carry drugs in a targeted, stimulus-responsive manner. Liposomes, dendrimers, micelles, carbon nanotubes, and polymeric nanoparticles are among the most common types of smart nanocarriers discussed in this study. Their design principles and functional features characterize the many forms of smart nanocarriers. Targeting techniques specific to breast cancer are highlighted, with a particular focus on active targeting via ligands and tumor microenvironment-responsive systems applicable to TNBC. By examining the integration of biodegradable materials, green synthesis methods, and alignment with the global Sustainable Development Goals (SDGs), the study also underscores the crucial role of sustainability in nanomedicine. Significant advancements have been made, but several biological, regulatory, and therapeutic issues still hinder the practical application of nanomedicine in treating TNBC. This review highlights key translational roadblocks and proposes strategic solutions to bridge the gap between the bench and the bedside.</p>","PeriodicalId":11357,"journal":{"name":"Drug Delivery and Translational Research","volume":" ","pages":"2527-2551"},"PeriodicalIF":6.9000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Delivery and Translational Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13346-025-02022-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Breast cancer remains one of the most prevalent causes of cancer-related mortality worldwide. Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer that has a poor prognosis and limited therapeutic options. Smart nanocarriers have been developed through significant advancements in nanotechnology over the past few years. To increase therapeutic effectiveness while reducing systemic toxicity, recent developments in nanotechnology have led to the creation of smart nanocarriers-nanosystems designed to carry drugs in a targeted, stimulus-responsive manner. Liposomes, dendrimers, micelles, carbon nanotubes, and polymeric nanoparticles are among the most common types of smart nanocarriers discussed in this study. Their design principles and functional features characterize the many forms of smart nanocarriers. Targeting techniques specific to breast cancer are highlighted, with a particular focus on active targeting via ligands and tumor microenvironment-responsive systems applicable to TNBC. By examining the integration of biodegradable materials, green synthesis methods, and alignment with the global Sustainable Development Goals (SDGs), the study also underscores the crucial role of sustainability in nanomedicine. Significant advancements have been made, but several biological, regulatory, and therapeutic issues still hinder the practical application of nanomedicine in treating TNBC. This review highlights key translational roadblocks and proposes strategic solutions to bridge the gap between the bench and the bedside.

三阴性乳腺癌中的智能纳米载体:靶向和转化应用的最新进展。
乳腺癌仍然是全世界癌症相关死亡的最普遍原因之一。三阴性乳腺癌(TNBC)是一种高度侵袭性的乳腺癌,预后差,治疗选择有限。在过去的几年里,通过纳米技术的重大进步,智能纳米载体已经被开发出来。为了提高治疗效果,同时减少全身毒性,纳米技术的最新发展导致了智能纳米载体的产生——纳米系统被设计成以靶向的、刺激反应的方式携带药物。脂质体、树状大分子、胶束、碳纳米管和聚合物纳米颗粒是本研究中讨论的最常见的智能纳米载体类型。它们的设计原理和功能特征表征了多种形式的智能纳米载体。强调了针对乳腺癌的靶向技术,特别关注通过配体和适用于TNBC的肿瘤微环境响应系统的主动靶向。通过研究生物可降解材料的整合、绿色合成方法以及与全球可持续发展目标(sdg)的一致性,该研究还强调了可持续性在纳米医学中的关键作用。纳米医学已经取得了重大进展,但一些生物学、调控和治疗方面的问题仍然阻碍了纳米医学在治疗TNBC中的实际应用。这篇综述强调了关键的转化障碍,并提出了弥合临床与临床之间差距的战略解决方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drug Delivery and Translational Research
Drug Delivery and Translational Research MEDICINE, RESEARCH & EXPERIMENTALPHARMACOL-PHARMACOLOGY & PHARMACY
CiteScore
11.70
自引率
1.90%
发文量
160
期刊介绍: The journal provides a unique forum for scientific publication of high-quality research that is exclusively focused on translational aspects of drug delivery. Rationally developed, effective delivery systems can potentially affect clinical outcome in different disease conditions. Research focused on the following areas of translational drug delivery research will be considered for publication in the journal. Designing and developing novel drug delivery systems, with a focus on their application to disease conditions; Preclinical and clinical data related to drug delivery systems; Drug distribution, pharmacokinetics, clearance, with drug delivery systems as compared to traditional dosing to demonstrate beneficial outcomes Short-term and long-term biocompatibility of drug delivery systems, host response; Biomaterials with growth factors for stem-cell differentiation in regenerative medicine and tissue engineering; Image-guided drug therapy, Nanomedicine; Devices for drug delivery and drug/device combination products. In addition to original full-length papers, communications, and reviews, the journal includes editorials, reports of future meetings, research highlights, and announcements pertaining to the activities of the Controlled Release Society.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书